Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: Evaluation of performance of INNO-LiPA HBV DR assay

Anna S F Lok, Fabien Zoulim, Stephen Locarnini, Alessandra Mangia, Grazia Niro, Hilde Decraemer, Geert Maertens, Frank Hulstaert, Karen De Vreese, Erwin Sablon

Research output: Contribution to journalArticle

138 Citations (Scopus)

Abstract

Sensitive and early detection of emerging hepatitis B virus (HBV) drug resistance may not only help monitor the viral dynamics associated with lamivudine treatment but could also improve therapeutic decision making. This is especially important when new antivirals effective against lamivudine-resistant HBV become available. A total of 159 serum samples from 33 chronic HBV patients receiving lamivudine treatment were analyzed at four centers for the presence of lamivudine-resistant mutations at codons 528 [180] (proposed revised nomenclature according to Stuyver et al. [Hepatology 33:751-757, 2001] shown in brackets), 552 [204], and 555 [207] of the HBV polymerase. Sequencing data were compared with results generated by the INNO-LiPA HBV DR line probe assay (LiPA), an assay based on reverse hybridization of amplified HBV DNA fragments with specific nucleotide probes immobilized on nitrocellulose strips. LiPA provided at least the same information as sequencing for 97.5% of all codons analyzed for codon 528 [180], 95% for codon 552 [204], and 100% for codon 555 [207]. The most common reason for discrepant or indeterminate results (0.4% and 1.5%, respectively) in a small percentage of the population tested could be attributed to polymorphisms not yet covered by LiPA probes. In at least five patients, a mutant could be detected earlier by LiPA than by sequencing. In 15 patients, LiPA detected mixed wild-type and mutant virus populations before viral breakthrough. These results demonstrate that INNO-LiPA HBV DR is a highly sensitive and easily applicable assay for the detection and monitoring of lamivudine-resistant mutations in chronic hepatitis B patients and that the assay is more sensitive than sequencing in detecting mixed mutant and wild-type sequences.

Original languageEnglish
Pages (from-to)3729-3734
Number of pages6
JournalJournal of Clinical Microbiology
Volume40
Issue number10
DOIs
Publication statusPublished - Oct 1 2002

Fingerprint

Lamivudine
Chronic Hepatitis B
Drug Resistance
Hepatitis B virus
Codon
Therapeutics
Mutation
Collodion
Gastroenterology
Terminology
Population
Antiviral Agents
Decision Making
Nucleotides
Viruses
DNA
Serum

ASJC Scopus subject areas

  • Microbiology (medical)
  • Microbiology

Cite this

Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy : Evaluation of performance of INNO-LiPA HBV DR assay. / Lok, Anna S F; Zoulim, Fabien; Locarnini, Stephen; Mangia, Alessandra; Niro, Grazia; Decraemer, Hilde; Maertens, Geert; Hulstaert, Frank; De Vreese, Karen; Sablon, Erwin.

In: Journal of Clinical Microbiology, Vol. 40, No. 10, 01.10.2002, p. 3729-3734.

Research output: Contribution to journalArticle

Lok, Anna S F ; Zoulim, Fabien ; Locarnini, Stephen ; Mangia, Alessandra ; Niro, Grazia ; Decraemer, Hilde ; Maertens, Geert ; Hulstaert, Frank ; De Vreese, Karen ; Sablon, Erwin. / Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy : Evaluation of performance of INNO-LiPA HBV DR assay. In: Journal of Clinical Microbiology. 2002 ; Vol. 40, No. 10. pp. 3729-3734.
@article{ad64cd71807047308a1d3f37841ceac4,
title = "Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: Evaluation of performance of INNO-LiPA HBV DR assay",
abstract = "Sensitive and early detection of emerging hepatitis B virus (HBV) drug resistance may not only help monitor the viral dynamics associated with lamivudine treatment but could also improve therapeutic decision making. This is especially important when new antivirals effective against lamivudine-resistant HBV become available. A total of 159 serum samples from 33 chronic HBV patients receiving lamivudine treatment were analyzed at four centers for the presence of lamivudine-resistant mutations at codons 528 [180] (proposed revised nomenclature according to Stuyver et al. [Hepatology 33:751-757, 2001] shown in brackets), 552 [204], and 555 [207] of the HBV polymerase. Sequencing data were compared with results generated by the INNO-LiPA HBV DR line probe assay (LiPA), an assay based on reverse hybridization of amplified HBV DNA fragments with specific nucleotide probes immobilized on nitrocellulose strips. LiPA provided at least the same information as sequencing for 97.5{\%} of all codons analyzed for codon 528 [180], 95{\%} for codon 552 [204], and 100{\%} for codon 555 [207]. The most common reason for discrepant or indeterminate results (0.4{\%} and 1.5{\%}, respectively) in a small percentage of the population tested could be attributed to polymorphisms not yet covered by LiPA probes. In at least five patients, a mutant could be detected earlier by LiPA than by sequencing. In 15 patients, LiPA detected mixed wild-type and mutant virus populations before viral breakthrough. These results demonstrate that INNO-LiPA HBV DR is a highly sensitive and easily applicable assay for the detection and monitoring of lamivudine-resistant mutations in chronic hepatitis B patients and that the assay is more sensitive than sequencing in detecting mixed mutant and wild-type sequences.",
author = "Lok, {Anna S F} and Fabien Zoulim and Stephen Locarnini and Alessandra Mangia and Grazia Niro and Hilde Decraemer and Geert Maertens and Frank Hulstaert and {De Vreese}, Karen and Erwin Sablon",
year = "2002",
month = "10",
day = "1",
doi = "10.1128/JCM.40.10.3729-3734.2002",
language = "English",
volume = "40",
pages = "3729--3734",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "10",

}

TY - JOUR

T1 - Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy

T2 - Evaluation of performance of INNO-LiPA HBV DR assay

AU - Lok, Anna S F

AU - Zoulim, Fabien

AU - Locarnini, Stephen

AU - Mangia, Alessandra

AU - Niro, Grazia

AU - Decraemer, Hilde

AU - Maertens, Geert

AU - Hulstaert, Frank

AU - De Vreese, Karen

AU - Sablon, Erwin

PY - 2002/10/1

Y1 - 2002/10/1

N2 - Sensitive and early detection of emerging hepatitis B virus (HBV) drug resistance may not only help monitor the viral dynamics associated with lamivudine treatment but could also improve therapeutic decision making. This is especially important when new antivirals effective against lamivudine-resistant HBV become available. A total of 159 serum samples from 33 chronic HBV patients receiving lamivudine treatment were analyzed at four centers for the presence of lamivudine-resistant mutations at codons 528 [180] (proposed revised nomenclature according to Stuyver et al. [Hepatology 33:751-757, 2001] shown in brackets), 552 [204], and 555 [207] of the HBV polymerase. Sequencing data were compared with results generated by the INNO-LiPA HBV DR line probe assay (LiPA), an assay based on reverse hybridization of amplified HBV DNA fragments with specific nucleotide probes immobilized on nitrocellulose strips. LiPA provided at least the same information as sequencing for 97.5% of all codons analyzed for codon 528 [180], 95% for codon 552 [204], and 100% for codon 555 [207]. The most common reason for discrepant or indeterminate results (0.4% and 1.5%, respectively) in a small percentage of the population tested could be attributed to polymorphisms not yet covered by LiPA probes. In at least five patients, a mutant could be detected earlier by LiPA than by sequencing. In 15 patients, LiPA detected mixed wild-type and mutant virus populations before viral breakthrough. These results demonstrate that INNO-LiPA HBV DR is a highly sensitive and easily applicable assay for the detection and monitoring of lamivudine-resistant mutations in chronic hepatitis B patients and that the assay is more sensitive than sequencing in detecting mixed mutant and wild-type sequences.

AB - Sensitive and early detection of emerging hepatitis B virus (HBV) drug resistance may not only help monitor the viral dynamics associated with lamivudine treatment but could also improve therapeutic decision making. This is especially important when new antivirals effective against lamivudine-resistant HBV become available. A total of 159 serum samples from 33 chronic HBV patients receiving lamivudine treatment were analyzed at four centers for the presence of lamivudine-resistant mutations at codons 528 [180] (proposed revised nomenclature according to Stuyver et al. [Hepatology 33:751-757, 2001] shown in brackets), 552 [204], and 555 [207] of the HBV polymerase. Sequencing data were compared with results generated by the INNO-LiPA HBV DR line probe assay (LiPA), an assay based on reverse hybridization of amplified HBV DNA fragments with specific nucleotide probes immobilized on nitrocellulose strips. LiPA provided at least the same information as sequencing for 97.5% of all codons analyzed for codon 528 [180], 95% for codon 552 [204], and 100% for codon 555 [207]. The most common reason for discrepant or indeterminate results (0.4% and 1.5%, respectively) in a small percentage of the population tested could be attributed to polymorphisms not yet covered by LiPA probes. In at least five patients, a mutant could be detected earlier by LiPA than by sequencing. In 15 patients, LiPA detected mixed wild-type and mutant virus populations before viral breakthrough. These results demonstrate that INNO-LiPA HBV DR is a highly sensitive and easily applicable assay for the detection and monitoring of lamivudine-resistant mutations in chronic hepatitis B patients and that the assay is more sensitive than sequencing in detecting mixed mutant and wild-type sequences.

UR - http://www.scopus.com/inward/record.url?scp=0036792186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036792186&partnerID=8YFLogxK

U2 - 10.1128/JCM.40.10.3729-3734.2002

DO - 10.1128/JCM.40.10.3729-3734.2002

M3 - Article

C2 - 12354872

AN - SCOPUS:0036792186

VL - 40

SP - 3729

EP - 3734

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 10

ER -